Beta-3 adrenergic receptor agonists for the prevention and therapy of pulmonary fibrosis

EP4750459A1Pending Publication Date: 2026-06-03UNIV DI PISA +2
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
UNIV DI PISA
Filing Date
2024-07-25
Publication Date
2026-06-03

AI Technical Summary

Technical Problem

Current treatments for bronchopulmonary dysplasia (BPD) and associated pulmonary fibrosis are only partially effective and lack specificity, with significant adverse effects, and there is a need for treatments that target collagen deposition in the lungs.

Method used

The use of beta-3 adrenergic receptor agonists, such as BRL 37344 and Vibegron, which act to prevent the onset and progression of pulmonary fibrosis by counteracting collagen fiber deposition in the pulmonary alveolar interstitium.

Benefits of technology

Activation of the beta-3 adrenergic receptor has been shown to exert an anti-fibrotic effect, significantly reducing hyperoxia-induced pulmonary fibrosis and mortality in animal models, while also being effective in vitro, thus providing a potential therapeutic option for BPD and related lung diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000015_0000
    Figure 00000015_0000
  • Figure 00000015_0001
    Figure 00000015_0001
  • Figure 00000016_0000
    Figure 00000016_0000
Patent Text Reader

Abstract

The present invention provides a beta-3 adrenergic receptor agonist, along with its pharmaceutical composition, for use in the treatment and / or prevention of pulmonary fibrosis, preferably pulmonary fibrosis associated with bronchopulmonary dysplasia (BPD).
Need to check novelty before this filing date? Find Prior Art